RISE Adult Medication Study
NCT01779362 on ClinicalTrials.gov · last registry update 2023-05-11
Finished February 2019, after enrolling 267 people. Primary outcome, as filed: ß-cell Response Measured by Hyperglycemic Clamp. liraglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- RISE Study Group
- Sponsor type
- Network
- Enrollment
- 267
- Started
- 2013-04
- Primary completion
- 2019-02 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
ß-cell Response Measured by Hyperglycemic Clamp
Conditions studied
Prediabetes · Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.